Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

Clinical Cancer Research

Volumn 12, Issue 12, 2006, Pages 3762-3773

  Piekarz, Richard L ^a   Frye, A Robin ^a   Wright, John J ^a   Steinberg, Seth M ^a   Liewehr, David J ^a   Rosing, Douglas R ^b   Sachdev, Vandana ^b   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; ST SEGMENT DEPRESSION; T CELL LYMPHOMA; T WAVE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; HEART; HUMANS; LYMPHOMA, T-CELL; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYOCARDIUM; RECURRENCE;

EID: 33745683507     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2095     Document Type: Article

References (56)

1. Sandor V, Senderowicz A, Merlins S, et al. P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83:817-25.
2. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-9.
3. 2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-83.
4. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
5. Wang C, Fu M, Angeletti RH, et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276:18375-83.
6. Piekarz RL, Robey RW, Zhan ZR, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-43.
7. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
8. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
9. Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999;94:1401-8.
10. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999;18:2461-70.
11. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32.
12. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
13. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
14. Keefe DL. The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist 2002;7:65-72.
15. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
16. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999;26:96-101.
17. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
18. Speyer J. Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 2002;20:1156-7.
19. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:655-8.
20. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609-15.
21. Arizona Uo Arizona Center for Education and Research on Therapeutics. June 8, 2005 http://www.torsades.org/.
22. Das G. QT interval and repolarization time in patients with intraventricular conduction delay. J Electrocardiol 1990;23:49-52.
23. Nosanchuk JS. False increases of troponin I attributable to incomplete separation of serum. Clin Chem 1999;45:714.
24. Borer JS, Bacharach SL, Green MV, Kent KM, Epstein SE, Johnston GS. Real-time radionuclide cineangiography in noninvasive evaluation of global and regional left-ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med 1977;296:839-44.
25. Sierra-Galan LM, Ingkanisorn WP, Rhoads KL, Agyeman KO, Arai AE. Qualitative assessment of regional left ventricular function can predict MRI or radionuclide ejection fraction: an objective alternative to eyeball estimates. J Cardiovasc Magn Reson 2003;5:451-63.
26. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
27. In: Agresti A, editor. Categorical data analysis. New York: Wiley; 1990. p. 347-75.
28. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 10 June 2004. http://www.fda.gov/cber/ gdIns/iche14qtc.htm.
29. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993;72:23-56.
30. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 London: May 25, 2005 http://www.emea.eu.int/pdfs/human/ich/000204en.pdf.
31. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
32. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
33. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758-63.
34. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-5.
35. Herman EH, Lipshultz SE, Rifai N, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998;58:195-7.
36. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999;17:2237-43.
37. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537-41.
38. Cooper HA, Braunwald E. Clinical importance of stunned and hibernating myocardium. Coron Artery Dis 2001;12:387-92.
39. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-9.
40. Morganroth J. Relations of QT(c) prolongation on the electrocardiogram to torsades-de-pointes: definitions and mechanisms. Am J Cardiol 1993;72:B10-3.
41. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
42. Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma 2002;43:1297-302.
43. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004;10:2289-98.
44. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
45. Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005;28:124-9.
46. Duvic M, Talpur R, Chiao N, Chiao J. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) forcutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood 2003;102:179a.
47. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88.
48. Rowinsky EK, de Bono J, Deangelo DJ, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 2005;22:Abstract #3131.
49. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22.
50. Steele N, Vidal L, Plumb J, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor PXD101 in patients with advanced solid tumours. J Clin Oncol 2005;22:3035.
51. Fischer T, Patnaik A, Bhalla K, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 2005;23:3106.
52. Sundaram S, Goldberger JJ. Risk stratification and epidemiology of sudden death. Curr Cardiol Rep 2004;6:333-8.
53. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110:479-88.
54. Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003;278:28930-7.
55. Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003;112:863-71.
56. Shizukuda Y, Piekarz RL, Bates SE, Sachdev V, Finkel T, Rosing DR. Effect of a histone deacetylase inhibitor on human cardiac mass. Cardiovasc Drugs Ther 2005;19:89-90.